H. Schmitz

No ORCID on file · 8 papers in corpus · active 2009-2019

Study types

  • article 8

Condition tags

  • endometriosis 8
  • chronic_pelvic_pain 2
  • dysmenorrhea 1
article 2019
Absence of Drug‐Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial
Journal of clinical pharmacology ·doi:10.1002/jcph.1396

Intravaginal rings (IVRs) are an established option for continuous administration of drugs in women. The combination of anastrozole (ATZ) and levonorgestrel (LNG) in an IVR with an intended 4-week wearing period has been considered for long…

article 2017
Efficacy, safety and tolerability of the CCR1 antagonist BAY 86‐5047 for the treatment of endometriosis‐associated pelvic pain: a randomized controlled trial
Acta obstetricia et gynecologica Scandinavica ·doi:10.1111/aogs.13105

INTRODUCTION: Antagonism of CC chemokine receptor type 1 (CCR1) may provide a novel treatment approach for women with symptomatic endometriosis. Studies of CCR1 antagonists in these patients have not been reported. MATERIAL AND METHODS: Wom…

article 2016
Model‐Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms
Journal of clinical pharmacology ·doi:10.1002/jcph.846

Pharmacokinetics (PK) of anastrozole (ATZ) and levonorgestrel (LNG) released from an intravaginal ring (IVR) intended to treat endometriosis symptoms were characterized, and the exposure-response relationship focusing on the development of …

article 2016
Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial
Human Reproduction ·doi:10.1093/humrep/dew145

STUDY QUESTION: What are suitable doses of the aromatase inhibitor anastrozole (ATZ) and the progestin levonorgestrel (LNG), when delivered to the systemic circulation by an intravaginal ring (IVR), for further clinical development as a pot…

article 2014
Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys
Human Reproduction ·doi:10.1093/humrep/deu315

Is it feasible to deliver anastrozole (ATZ), an aromatase inhibitor (AI), by a vaginal polymer-based drug delivery system in the cynomolgus monkey (Macaca fascicularis) to describe the pharmacokinetic profile? The present study showed the e…

article 2012
How can we measure endometriosis-associated pelvic pain?
·doi:10.5301/je.2012.9725

Purpose The aim of our work was to explore which of the most commonly used pain scales is best suited to assess treatment success in endometriosis therapy and, therefore, qualifies best to be used as primary endpoint for clinical studies in…

article 2010
Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials
Health and quality of life outcomes ·doi:10.1186/1477-7525-8-138

BACKGROUND: When comparing active treatments, a non-inferiority (or one-sided equivalence) study design is often used. This design requires the definition of a non-inferiority margin, the threshold value of clinical relevance. In recent stu…

article 2009
O341 Minimally clinically important difference for endometriosis associated pelvic pain measured on a visual analogue scale
·doi:10.1016/s0020-7292(09)60713-x